Last reviewed · How we verify

NCT06327789

Trunk Control and Disability in Persons With Multiple Sclerosis

Completed Last updated 25 March 2024
What this trial tests

trial in Multiple Sclerosis in 23 participants. Completed in 21 February 2022.

Timeline
21 December 2021
Primary endpoint
25 December 2021
21 February 2022

Quick facts

Lead sponsorZonguldak Bulent Ecevit University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment23
Start date21 December 2021
Primary completion25 December 2021
Estimated completion21 February 2022
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Zonguldak Bulent Ecevit University

Who can join

Adults 18 to 50, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the relationship between physical disability and trunk control, balance, and pedobarographic parameters in persons with Relapsing Remitting Multiple Sclerosis (RRMS) who have a low Expanded Disability Status Scale (EDSS) score. Twenty-three RRMS patients with an age range of 18-50 years, EDSS score ≤ 3 were included in this study. The patients' level of disability (EDSS), trunk control )Trunk Impairment Scale - TIS), lower extremity functionality (Timed 25-Foot Walk Test - T25FW), upper extremity functionality (Nine Hole Peg Test- 9HPT), balance (Biodex Balance System) and gait (Zebris® FDM 2) were evaluated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other Zonguldak Bulent Ecevit University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06327789.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing